AVBP – arrivent biopharma, inc. (US:NASDAQ)
Stock Stats
News
ArriVent BioPharma, Inc. (NASDAQ: AVBP) was upgraded by analysts at B. Riley to a "strong-buy" rating.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at B. Riley. They set a "buy" rating and a $37.00 price target on the stock.
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts [Yahoo! Finance]
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Guggenheim. They set a "buy" rating and a $45.00 price target on the stock.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.
Form 8-K ArriVent BioPharma, Inc. For: Mar 11
Form S-8 ArriVent BioPharma, Inc.
Form 8-K ArriVent BioPharma, Inc. For: Mar 03
Form 10-K ArriVent BioPharma, Inc. For: Dec 31
Form SCHEDULE 13G ArriVent BioPharma, Inc. Filed by: Novo Holdings A/S
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.